P53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up

World Journal of Gastroenterology

Volumn 17, Issue 16, 2011, Pages 2143-2149

  Guan, Yong Song ^a   Liu, Yuan ^a   He, Qing ^a   Li, Xiao ^a   Yang, Lin ^a   Hu, Ying ^a   La, Zi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Adenovirus p53; Clinical trial; Hepato cellular carcinoma; P53 gene therapy; Transcatheter hepatic arterial chemo embolization

Indexed keywords

ADENOVIRUS VECTOR; FLUOROURACIL; GENDINCE; IODINATED POPPYSEED OIL; NAVELBINE; PROTEIN P53; RECOMBINANT ADENOVIRUS P53; UNCLASSIFIED DRUG;

ADENOVIRUS; ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER PAIN; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MYALGIA; OUTCOME ASSESSMENT; RISK ASSESSMENT; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

EID: 79955937471     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i16.2143     Document Type: Article

References (31)

1. Robson T, Hirst DG. Transcriptional Targeting in Cancer Gene Therapy. J Biomed Biotechnol 2003; 2003: 110-137
2. Zhang SW, Xiao SW, Liu CQ, Sun Y, Su X, Li DM, Xu G, Cai Y, Zhu GY, Xu B, Lü YY. Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases. Zhonghua Yixue Zazhi 2003; 83: 2023-2028
3. Chen CB, Pan JJ, Xu LY. [Recombinant adenovirus p53 agent injection combined with radiotherapy in treatment of nasopharyngeal carcinoma: a phase II clinical trial]. Zhong-hua Yixue Zazhi 2003; 83: 2033-2035
4. Cancer gene therapy is first to be approved. Available from: URL: http://www.lucifer.com/pipermail/ectropy-chat/at-tachments/20030019/ee07cea0/attachment.htm
5. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 2000; 88: 1574-1581
6. Takayasu K, Arii S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K, Sato M, Yamanaka N, Shimamura Y, Ohto M. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000; 175: 699-704
7. Sobin LH, Wittekind CH, editors. UICC TNM classifcation of malignant tumours. 5th ed. New York: John Wiley and Sons, 1997
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
9. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
10. Li L, Wu PH, Li JQ, Zhang WZ, Lin HG, Zhang YQ. Segmental transcatheter arterial embolization for primary hepatocellular carcinoma. World J Gastroenterol 1998; 4: 511-512
11. Mizoe A, Yamaguchi J, Azuma T, Fujioka H, Furui J, Kanematsu T. Transcatheter arterial embolization for advanced hepatocellular carcinoma resulting in a curative resection: report of two cases. Hepatogastroenterology 2000; 47: 1706-1710
12. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442
13. Qian J, Truebenbach J, Graepler F, Pereira P, Huppert P, Eul T, Wiemann G, Claussen C. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoemboliza-tion in an animal model of hepatocellular carcinoma. World J Gastroenterol 2003; 9: 94-98
14. Fan J, Ten GJ, He SC, Guo JH, Yang DP, Wang GY. Arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 1998; 4: 33-37
15. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepato-cellular carcinoma. J Gastroenterol Hepatol 1997; 12: S319-S328
16. Ahrar K, Gupta S. Hepatic artery embolization for hepa-tocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin N Am 2003; 12: 105-126
17. Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1885-1891
18. Chen XM, Luo PF, Lin HH, Zhou ZJ, Shao PJ, Fu L, Li WK. [Long-term result of combination of transcatheter arterial chemoembolization and percutaneous ethanol injection for treatment of hepatocellular carcinoma]. Ai Zheng 2004; 23: 829-832
19. Guo WJ, Yu EX, Liu LM, Li J, Chen Z, Lin JH, Meng ZQ, Feng Y. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1697-1701
20. Kouraklis G. Progress in cancer gene therapy. Acta Oncol 1999; 38: 675-683
21. Friedmann T. Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 1992; 70: 1810-1817
22. Hsia CC, Nakashima Y, Thorgeirsson SS, Harris CC, Minemura M, Momosaki S, Wang NJ, Tabor E. Correlation of im-munohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncol Rep 2000; 7: 353-356
23. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810
24. Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 1995; 14: 275-285
25. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996; 112: 1372-1376; discussion 1376-1377
26. Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, Huang SF, Chui AK, Law DJ, Li YG, Lau WY, Li AK. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol 2003; 162: 1823-1829
27. Jeng KS, Sheen IS, Chen BF, Wu JY. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg 2000; 135: 1329-1333
28. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, Ji Y, Huang LW, Jia HL, Sun HC, Wang L. P53 immunohisto-chemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 2002; 8: 459-463
29. Sheen IS, Jeng KS, Wu JY. Is p53 gene mutation an indicati-or of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol 2003; 9: 1202-1207
30. Guan YS, Liu Y, Zhou XP, Li X, He Q, Sun L. p53 gene (Gendicine) and embolisation overcame recurrent hepato-cellular carcinoma. Gut 2005; 54: 1318-1319
31. Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, Asahara T, Kajiyama G. Long-term prognosis of patients undergoing transcatheter arterial chemoemboliza-tion for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochlo-ride emulsion. J Vasc Interv Radiol 2001; 12: 847-854